Azra Borogovac

Born in Bosnia-Herzegovina, grew up in Boston, now Assistant Prof hematology/HSCT @CityofHopeOC in Irvine, CA | alum of @UMASSChan @StephensonCC

[Azra Borogovac @AzraBoro88]

@RahulBanerjeeMD Thanks for your support!! Glad you had a good time!

[Bosnian Football @BosniaNTBall]

Oh how lucky we are to be able to live this and feel this!❤️🇧🇦⚜️ #FIFAWorldCup

[Sumanta K. Pal, MD, FASCO @montypal]

Fantastic talk by @AbhiTrip87 at @AUC3_Official. Terrific insights into contemporary management of IO-refractory advanced #bladdercancer - a complicated space indeed. All star panel with @jackiebrown_MD, @MichvdHeijden, @bergsa83, @DanielPetrylak & @tompowles1. Proud to see both he & @WesleyYipMD representing @cityofhope so well - many thx to @DrRanaMcKay & @DrChoueiri for the opportunity!

[Murali Janakiram @JanakiramMurali]

@bdermanmd MRD based stopping maintenance
- makes a strong case for stopping in MRD neg- sustained MRD neg, no HR features, PET neg
- but we should and can stop earlier with effective Rx. we should think about this more
#ASH25

[Mike Thompson, MD, PhD, FASCO @mtmdphd]

Safety and efficacy of out-of-specification ciltacabtagene autoleucel (cilta-cel) in Relapsed/Refractory multiple myeloma (RRMM) [Nov 3, 2025] @AzraBoro88 et al. #ASH25 abs25-12050
https://t.co/xtnKvlhnTD #mmsm #CARTcell n=40

[Dr. Amrita Krishnan @DoctorAKrishnan]

@cityofhopeoc :
it’s a FACT we are doing HCT thanks to this great team

[Charles Nguyen @charlesbnguyen]

Very honored to have received the @PCF_Science Young Investigator Award!

Incredibly grateful for my mentorship team led by @TDorffOnc! Also thankful for all my current and past mentors/teachers for the support.

@cityofhope @cityofhopeoc

[Ash Alizadeh, MD/PhD 🇺🇸 @AshAlizadeh]

Honored to share our newly published manuscript https://t.co/xAH8RPTQNf which demonstrates that circulating tumor DNA (ctDNA) by PhasED-Seq offers the most precise definition of remission after frontline therapy for patients with large B-cell lymphoma (LBCL) out now in @JCO_ASCO. #ctDNA detection of #MRD. 1/18

[Jason Westin, MD FACP FASCO @Lymphoma_Doc]

The SUNMO trial manuscript is now published at @JCO_ASCO! Mosun-Pola is superior to RGemOx in patients with ref/rel LBCL with 3X progression free survival and 2x complete response rates. Only 4% had CRS more than a fever. #lymsm
@elizabeth_budde
https://t.co/7u02KikJmE

[City of Hope | Orange County @cityofhopeoc]

Treatment can be difficult, and everyone finds something that helps them get through. For grateful patient Ray Hartjen, it’s music. Listening, composing and playing takes him to a place of peace, even on the hardest days, and reminds him there is still beauty, light, and hope. 💙

[Murali Janakiram @JanakiramMurali]

@DoctorAKrishnan is an amazing mentor, colleague and a leader of the City of Hope Myeloma @cityofhopeoc program and a national leader. Very pleased she is the SWOG chair and looking forward to the collaboration.

[Abhishek Tripathi @AbhiTrip87]

Incredibly grateful to the mentorship and support from entire @eaonc #GU team @ChrisSweens1 @cityofhope @CityofHope_GU @montypal @DrRaviSalgia @TDorffOnc

[OncoAlert @OncoAlert]

Ten-year survival rates by PSA nadir in patients with metastatic hormone-sensitive prostate cancer: long-term survival analysis from the ECOG-ACRIN 3805 (CHAARTED) trial

https://t.co/0UaletgdGb

The 10-year follow-up of the CHAARTED trial confirms that adding docetaxel to androgen deprivation therapy significantly improves overall survival in patients with high-volume metastatic hormone-sensitive prostate cancer, while PSA nadir <0.2 ng/mL at 6 months emerged as a powerful independent predictor of long-term survival across both treatment arms.

Achieving this low PSA was strongly associated with better outcomes regardless of baseline prognostic factors, and docetaxel increased the likelihood of reaching this threshold, supporting the use of PSA nadir as a key marker for response assessment and potential response-adapted treatment strategies. #ProstateCancer

@montypal @crisbergerot @DrDanielHeng @apolo_andrea @DrChoueiri @PGrivasMDPhD @TiansterZhang @HHammersMD @ravikanesvaran @neerajaiims @amerseburger @sonpavde @drenriquegrande @scserendipity1 @Silke_Gillessen
@EfstathiouEleni @tompowles1 @BraunMDPhD @cdanicas
@DrYukselUrun

#OncoAlertAF
@nataliagandur @acampsmalea @BRicciutiMD
@yekeduz_emre @HHorinouchi @FadiHaddad_MD
@Abdallah81MD @FernandoOnco
@ElisaAgostinett @to_be_elizabeth @bavilima @realbowtiedoc @Erman_Akkus @Lucarecco @GaiaGriguolo @JankovicK
@MarioBalsaMD @DrMirallas @GIMedOnc @OscarTahuahua

[Rahul Banerjee, MD, FACP @RahulBanerjeeMD]

1/ Excellent news for 🇺🇸 patients receiving CAR-T therapy!

FDA has listened to data and relaxed CRS monitoring and driving restrictions for liso-cel for #lymsm / ide-cel for #MMsm.

Huge step to lower time toxicity and disparities.

Can this be fixed for all CAR-T products?

[Azra Borogovac @AzraBoro88]

Energizing session with @DoctorAKrishnan diving into bispecific antibodies in multiple myeloma —bridging community and academic expertise across @cityofhope network! @cityofhopeoc @CancerNetwrk
#MultipleMyeloma

[Sumanta K. Pal, MD, FASCO @montypal]

I joined @cityofhope when our world-class #HelfordHospital in #Duarte opened 20y ago. Then, I had the honor of seeing the first pts at our #NewportBeach site 5y ago & then our #Irvine site 2y ago. Soon, our @cityofhopeoc hospital will open. A truly momentous occasion that will bring state of the art oncology care to #OrangeCounty - today’s key ceremony was the beginning of that chapter!

[Blood Journals Portfolio @BloodPortfolio]

Cyclophosphamide to ablate CAR T cells is an effective strategy to mitigate steroid-refractory neurotoxicity syndrome neurotoxicities. https://t.co/x85jip2w8e #clinicaltrialsandobservations #immunobiologyandimmunotherapy

[Rafael Fonseca MD 🦔🇺🇸🏜🇲🇽 @Rfonsi1]

Amazing response rates with trispecific antibody JNJ-5322 in RR MM. N. van de Donk suggest it is as effective as BCMA targeting CART. In fections are still quite high. All patients should get prophylactic IgG replacement. 12 months PFS of 95%. Prophylactic toci significantly reduced CRS, no ICANS seen.
#ASCO25

[City of Hope | Orange County @cityofhopeoc]

Amrita Krishnan, M.D., our executive medical director of hematology, has hope after witnessing remarkable progress in myeloma treatment—helping patients achieve dreams, from weddings to graduations.💙

What gives you hope? We'd love to hear! 💬

Learn more:https://t.co/f83Cls53KB